JNJ-16241199

Overview

JNJ-16241199 (R306465) is an orally active, selective hydroxamate-based histone deacetylase ( HDAC ) inhibitor, with the IC 50 of 3.3 nM and 23 nM for HDAC1 and HDAC8 , respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 waf1 , cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 induces cell apoptosis and shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-10226
• CAS No.: 604769-01-9
• Molecular Formula: C19H19N5O4S
• Molecular Weight: 413.45
• Purity: 99.05%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source